Clinical Trial · NCT04266392

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Overview

Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer for prostate cancer (\[18F\]-DCFPyl) combined with magnetic resonance imaging (MRI). Results of tracer uptake and MRI image features as whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on conventional imaging modalities. Additionally, if the patient undergoes a biopsy as standard of care, image features will correlate directly with histopathological findings.Validation of this radiotracer can potentially lead to its use as a standard of care for future imaging and improve diagnosis and treatment guidance.This drug is not approved by the Food and Drug Administration (FDA) and is therefore considered experimental.There will be 20 subjects enrolled in this study; all of these patients will be enrolled at Stony Brook University Medical Center.

Sponsor

Stanford University

Phase

Early Phase 1

Contacts

Dinko Franceschi, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04266392

Drug / Compound

DCFPyl

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

subject has prostate cancer treated with surgery, radiation therapy and/or chemotherapy for localized disease
subject has biochemical recurrence defined in postsurgical patients as a PSA value = \> 0.2 ng/mL followed by a subsequent confirmatory PSA value = \>0.2 ng/mL according to the American Urological Association (AUA) guidelines, or three consecutive rises above the nadir in patients following radiation therapy according to the American Society for Radiation Therapy and Oncology (ASTRO).
in most cases, it will be required that the patient has had a prior CIM scan (such as a BS, MRI, CT or PET with F-18 Fluciclovine) performed before enrollment in this study; the only exception would be if the PSA level of the patient is remarkably high indicating apparent recurrence.

Exclusion

if they have had treatment with investigational drug within 30 days prior to trial enrollment;
is unable to lie comfortably on a bed inside the scanner for 60 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis);
ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or ferromagnetic objects such as jewelry or metal clips in clothing;
if they had administration of another radioisotope within five physical half-lives of trial enrollment;
any contraindications to MRI imaging such as electrical implants, cardiac pacemakers or perfusion pumps;
if they had radiation or chemotherapy within 4 weeks prior to trial enrollment;Eligibility will be determined by a screening interview. All subjects recruited for the study will be able to withdraw from the study at any time.